Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iptacopan in idiopathic immune complex mediated membranoproliferative glomerulonephritis (IC-MPGN)
2022-502160-20-00Phase 3Authorised
- Sponsor
- Novartis
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 23
01
Overview
Phase 3, randomised, double-blind trial in Primary immune complex membranoproliferative glomerulonephritis (MPGN) comparing Iptacopan with Placebo (2 arms). Primary endpoint: Log-transformed ratio to baseline in UPCR at 6 months. Planned start Sep 2023; status: authorised.
02
Drugs
Iptacopan
03
Conditions
Primary immune complex membranoproliferative glomerulonephritis (MPGN)
Beyond the preview
Go deeper on 2022-502160-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502160-20-00.